Terms: = Prostate cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH
212 results:
1. Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE).
Ingrosso G; Ponti E; Francolini G; Caini S; Fondelli S; Santini R; Valeriani M; Rago L; Duroni G; Bruni A; Augurio A; Tramacere F; Trippa F; Russo D; Bottero M; Tamburo M; Parisi S; Borghesi S; Lancia A; Gomellini S; Scoccianti S; Stefanacci M; Vullo G; Statuto T; Miranda G; Santo B; Di Marzo A; Bellavita R; Vinciguerra A; Livi L; Aristei C; Bertini N; Orsatti C; Detti B
Radiol Med; 2024 Apr; 129(4):643-652. PubMed ID: 38369638
[TBL] [Abstract] [Full Text] [Related]
2. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract] [Full Text] [Related]
3. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T; Mori K; Yasue K; Matsukawa A; Fukuokaya W; Yanagisawa T; Hata K; Murakami M; Koike Y; Miki J; Yamada H; Kimura T
Int J Clin Oncol; 2024 Feb; 29(2):213-221. PubMed ID: 38103156
[TBL] [Abstract] [Full Text] [Related]
4. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K; Azad AA; Matsubara N; Carles J; Fay AP; De Giorgi U; Joung JY; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Ye D; Lin X; Healy CG; Di Santo N; Laird AD; Zohren F; Agarwal N
Nat Med; 2024 Jan; 30(1):257-264. PubMed ID: 38049622
[TBL] [Abstract] [Full Text] [Related]
5. Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
Fernando M; Anton A; Weickhardt A; Azad AA; Uccellini A; Brown S; Wong S; Parente P; Shapiro J; Liow E; Torres J; Goh J; Parnis F; Steer C; Warren M; Gibbs P; Tran B
J Geriatr Oncol; 2023 Nov; 14(8):101621. PubMed ID: 37683368
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive analysis of predictive factors for upstaging in intraprostatic cancer after radical prostatectomy: Different patterns of spread exist in lesions at different locations.
Wu S; Jiang Y; Liang Z; Chen S; Sun G; Ma S; Chen K; Liu R
Cancer Med; 2023 Sep; 12(17):17776-17787. PubMed ID: 37537798
[TBL] [Abstract] [Full Text] [Related]
7. A pilot study of an organised population-based testing programme for prostate cancer.
Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A
BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331
[TBL] [Abstract] [Full Text] [Related]
8. An Examination of Racial and Ethnic Disparities in the Use of prostate Biopsy and Magnetic Resonance Imaging in prostate cancer Screening.
Chartrand N; Stecher C; Rajendra S; Rosenkrantz AB; Duszak R; Hughes DR
Urol Pract; 2023 Nov; 10(6):612-619. PubMed ID: 37498656
[TBL] [Abstract] [Full Text] [Related]
9. Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
Matsuyama H; Matsubara N; Kazama H; Seto T; Sunaga Y; Suzuki K
BMC Cancer; 2023 Jun; 23(1):538. PubMed ID: 37308888
[TBL] [Abstract] [Full Text] [Related]
10. Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.
Panunzio A; Tappero S; Hohenhorst L; Cano Garcia C; Piccinelli M; Barletta F; Tian Z; Tafuri A; Briganti A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Kapoor A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Urol Oncol; 2023 Feb; 41(2):110.e7-110.e14. PubMed ID: 36456452
[TBL] [Abstract] [Full Text] [Related]
11. Cardiac Biomarkers and Geriatric Assessment in Metastatic Castrate-Resistant prostate cancer During Abiraterone Acetate Therapy - A Cardio-Oncology Study.
Wilk M; Waśko-Grabowska A; Skoneczna I; Szczylik C; Szmit S
Cancer Control; 2022; 29():10732748221140696. PubMed ID: 36447439
[TBL] [Abstract] [Full Text] [Related]
12. [Adhesion of urologists to the recommendations of the French Urological Association cancer Committee (CCAFU) in the imaging work-up of localized prostate cancer].
Trétarre B; Trouche-Sabatier SG; Foucan AS; Abdo N; Poinas G; Rébillard X; Azria D; Iborra F
Prog Urol; 2022 Dec; 32(16):1446-1454. PubMed ID: 36344379
[TBL] [Abstract] [Full Text] [Related]
13. [cancer survival during 2012-2018 in cancer registries of Shandong Province].
Jiang F; Fu ZT; Lu ZL; Chu J; Guo XL; Xu A
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):806-814. PubMed ID: 35785863
[No Abstract] [Full Text] [Related]
14. Retzius-Sparing
Turkolmez K; Akpinar C; Kubilay E; Suer E
J Endourol; 2022 Sep; 36(9):1214-1222. PubMed ID: 35546454
[No Abstract] [Full Text] [Related]
15. Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
Kazama H; Kawaguchi O; Seto T; Suzuki K; Matsuyama H; Matsubara N; Tajima Y; Fukao T
BMC Cancer; 2022 Apr; 22(1):470. PubMed ID: 35484517
[TBL] [Abstract] [Full Text] [Related]
16. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
Shayegan B; Wallis CJD; Hamilton RJ; Morgan SC; Cagiannos I; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Roy S; Noonan KL; Niazi T; Hotte SJ; Saad F; Hew H; Park-Wyllie L; Chan KFY; Malone S
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):74-79. PubMed ID: 35197558
[TBL] [Abstract] [Full Text] [Related]
17. Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System cancers.
Min Z; Mi Y; Lv Z; Sun Y; Tang B; Wu H; Zhang Z; Pan H; Zhang Y; Lu C; Zuo L; Zhang L
Dis Markers; 2022; 2022():1720851. PubMed ID: 35082928
[TBL] [Abstract] [Full Text] [Related]
18. Effect of
Metser U; Zukotynski K; Mak V; Langer D; MacCrostie P; Finelli A; Kapoor A; Chin J; Lavallée L; Klotz LH; Hagerty M; Hildebrand C; Bauman G
Radiology; 2022 May; 303(2):414-422. PubMed ID: 35076300
[TBL] [Abstract] [Full Text] [Related]
19. Nerve spare robot assisted laparoscopic prostatectomy with amniotic membranes: medium term outcomes.
Noël J; Mascarenhas A; Patel E; Reddy S; Sandri M; Bhat S; Moschovas M; Rogers T; Ahmed S; Stirt D; Patel V
J Robot Surg; 2022 Oct; 16(5):1219-1224. PubMed ID: 35015249
[TBL] [Abstract] [Full Text] [Related]
20. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
[TBL] [Abstract] [Full Text] [Related]
[Next]
